Lung Cancer Highlights, 2011 by Dr. Weiss, Part 2: ALK and other New Molecular Targets

Article and Video CATEGORIES

Cancer Journey

ABOUT

Howard Jack West, MD, Founder, Board President

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

Lung Cancer Highlights, 2011 by Dr. Weiss, Part 2: ALK and other New Molecular Targets

Dr West

Sun, 03/18/2012 - 11:28

Author

Howard (Jack) West, MD

Here is the second part of the presentation on "Lung Cancer Highlights, 2011" by Dr. Jared Weiss. This section of his talk focuses on the striking story of the identification of the ALK rearrangement as a relevant target in lung cancer, along with an impressive treatment for this subgroup, and other new targets, such as ROS-1.

Below you'll find the audio and video versions of the podcast, as well as the transcript and figures.

Dr. Weiss Lung Cancer Highlights 2011, Pt 2 ALK and New Molecular Targets Audio Podcast

Dr. Weiss Lung Cancer Highlights 2011, Pt 2 ALK and New Molecular Targets Transcript

Dr. Weiss Lung Cancer Highlights 2011 Pt 2 ALK and New Molecular Targets Figs

The third and final part of Dr. Weiss's presentation will focus on advances for broader populations: smokers and the elderly. He'll cover the lung cancer screening trial known as the NLST, as well as an influential presentation of single agent vs. doublet chemotherapy in elderly patients with advanced NSCLC. Look for that here very soon.

Thanks again to LUNGevity Foundation for their sponsorship of this work with us, making this content possible.

Next Previous link

Previous Post Next Post

Article

Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.

Videoteca de Cáncer de Pulmón en Español 2025

Video

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.

Unlocking Precision in Lung Cancer: Understanding and Overcoming Resistance to EGFR and ALK Inhibitors

Article

The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.